Startups
IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP).
Participate in the leading infectious diseases event of the year - IDWeek 2022!
IDWeek attendees represent all facets of ID research and treatment from the bench to the bedside. IDWeek 2022 will be a live and in person in Washington, DC on Oct. 19-23 and will continue its mission of advancing science and improving care. IDWeek is the must attend event for individuals and organizations operating in the ID space.
Participate in the leading infectious diseases event of the year - IDWeek 2022!
IDWeek attendees represent all facets of ID research and treatment from the bench to the bedside. IDWeek 2022 will be a live and in person in Washington, DC on Oct. 19-23 and will continue its mission of advancing science and improving care. IDWeek is the must attend event for individuals and organizations operating in the ID space.
Overview
Location
United States, Virginia, Arlington
Employees
51-200
Founded date
2012
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 20, 2025 | New Jersey’s ID Care Continues to Advance Infectious Disease Medicine at IDWeek 2025 | Clinicians from around the world gather for the annual meeting to bring innovation & compassion to the forefront while improving patient care & public health Every discussion at IDWeek ultimately serves one purpose: to improve and a... |
| Nov 24, 2024 | Everest Medicines: Pioneering Solutions in the Battle Against Disease | In the ever-evolving landscape of biopharmaceuticals, Everest Medicines stands as a beacon of hope. This Shanghai-based company is on a mission to tackle some of the most pressing health challenges in Asia. With innovative therapies like er... |
| Nov 22, 2024 | Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity | SHANGHAI, Nov. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of i... |
| Aug 5, 2024 | Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update | Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024 New SPR720 in-vitro resistance data to be presented at I... |
| Oct 18, 2022 | Biotia to Present Clinical Validation Data at IDWeek 2022 Annual Meeting | We are delighted that we were selected to present our clinical validation data and clinical-grade metagenomics tool that enables more accurate detection of pathogens in urine samples compared to culture. NEW YORK (PRWEB) October 18, 2022 Bi... |
| Oct 11, 2022 | Clear Labs to Present at IDWeek on Role of Whole Genome Sequencing in Hospitals | Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is announcing plans to attend key events in October. SAN CARLOS, Calif. (PRWEB) October 11, 2022 Clear Labs, the l... |
| Nov 1, 2021 | There’s no Delta-specific booster coming to save you – what we have is good enough | Nurse Alix Zacharski receives a Pfizer COVID-19 booster shot in Miami, Florida on October 5, 2021. AP Photo/Lynne Sladky The technology behind Pfizer and Moderna’s vaccines makes it easy to tweak shots to target coronavirus variants. Curren... |
| Oct 28, 2021 | A nasal COVID-19 vaccine could be the solution to ending the pandemic, experts say, and early trial data looks promising | Meissa is developing a nasal vaccine against COVID-19. But it’s still in the earliest phase of human testing. Meissa Vaccines COVID-19 vaccines are great at preventing severe illnesses and death. But they don’t always stop transmission or m... |
| Sep 29, 2021 | ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021 | Data Being Presented Demonstrates Directly Positive Clinical Utility and Furthers the Understanding of Exebacase in Treating Staphylococcus aureus Bacteremia, Including Multidrug-Resistant MRSA YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE)... |
Show more
Reviews 0
FAQ about IDWeek
When was IDWeek founded?
IDWeek was founded in 2012.
What has the press written about IDWeek?
Parsers VC has collected 12 articles mentioning IDWeek, among them “New Jersey’s ID Care Continues to Advance Infectious Disease Medicine at IDWeek 2025” (Oct 20, 2025) and “Everest Medicines: Pioneering Solutions in the Battle Against Disease” (Nov 24, 2024).
Is IDWeek still active?
Yes, IDWeek is active; its latest activity on Parsers VC dates from Oct 14, 2026.